FDA delaying intended use regulation

FDA announced Friday that it is delaying the implementation of a proposed rule defining the “intended use” of medical products. The delay means that FDA is reconsidering language that drug companies complained would create unnecessary legal jeopardy and is inconsistent with free speech protections under the First Amendment to the U.S. Constitution (see BioCentury Extra, Feb. 9, 2017)...